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Background: Boron neutron capture therapy (BNCT) is a molecular radiation treatment based on the 10B (n, α) 7Li
nuclear reaction in cancer cells, in which delivery of 10B by 4-borono-phenylalanine conjugated with fructose
(BPA-fr) to the cancer cells is of critical importance. The PET tracer 4-borono-2-18 F-fluoro-phenylalanine (FBPA) has
been used to predict the accumulation of BPA-fr before BNCT. However, because of the difference in chemical
structure between BPA-fr and FBPA and the difference in the dose administered between BPA-fr (therapeutic dose)
and FBPA (tracer dose), the predictive value of FBPA PET for BPA-fr accumulation in the tumor and normal tissues is
not yet clearly proven. We conducted this study to validate FBPA PET as a useful test to predict the accumulation
of BPA-fr in the tumor and normal tissues before BNCT.
Methods: RGC-6 rat glioma cells (1.9 × 107) were implanted subcutaneously in seven male F344 rats. On day 20 after
the tumor implantation, dynamic PET scan was performed on four rats after injection of FBPA for 1 h. Whole-body
PET/CT was performed 1 h after intravenous injection of the FBPA solution (30.5 ± 0.7 MBq, 1.69 ± 1.21 mg/kg). PET
accumulation of FBPA in the tumor tissue and various normal tissues was estimated as a percentage of the injected
dose per gram (%ID/g). One hour after the PET/CT scan, BPA-fructose (167.32 ± 18.65 mg/kg) was injected
intravenously, and the rats were dissected 1 h after the BPA-fr injection. The absolute concentration of 10B in the
autopsied tissues and blood was measured by inductively coupled plasma optical emission spectrometry (ICP-OES).
Results: The highest absolute concentration of 10B determined by ICP-OES was found in the kidney
(4.34 ± 0.84 %ID/g), followed by the pancreas (2.73 ± 0.63 %ID/g), and the tumor (1.44 ± 0.44 %ID/g). A significant
positive correlation was found between the accumulation levels of BPA-fr and FBPA (r = 0.91, p < 0.05).
Conclusions: FBPA PET can reliably predict accumulation of BPA-fr in the tumor as well as normal tissues.
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Boron neutron capture therapy (BNCT) is based on the
nuclear capture reaction of 10B (n, α) 7Li by low-energy
neutrons produced by a nuclear reactor or more recently
accelerator. High-energy α particles and lithium ions have
been shown to exert a cell-killing effect. In the presence of
10B specifically in cancer cells, these particles have been* Correspondence: hatazawa@tracer.med.osaka-u.ac.jp
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because of the short track ranges of these particles (9 to
10 μm for α particles and 4 to 5 μm for 7Li nuclei) [1-3].
In BNCT, the requisite concentration of 10B in the
tumor has been estimated to be 15 ppm or more [2]. It
is also important to estimate the 10B concentration in
normal tissues/organs to avoid radiation injury to nor-
mal tissues [4-6].
In the present BNCT practice, L-paraboronopheny-
lalanine labeled with 10B and conjugated with fructose
(BPA-fr) is mainly used as the carrier of 10B into thes an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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the tumors, 4-borono-2-18 F-fluoro-phenylalanine (FBPA)
PET has been employed [4]. Imahori et al. demonstrated
that both BPA-fr and FBPA accumulated in high concen-
tration in high-grade gliomas [5]. In clinical practice, the
measurement of FBPA accumulation was made about 1 h
after FBPA administration [7-10]. However, there are sev-
eral limitations of FBPA PET in predicting BPA-fr accu-
mulation in the tumors and normal tissues. Firstly, the
chemical structure of FBPA differs from that of BPA-fr.
Secondly, FBPA PET provides tracer-dose pharmacokinet-
ics of FBPA, while therapeutic doses of 10BPA are admin-
istered (approximately 500 mg/kg) for BNCT. Thirdly,
BPA-fr is administered by slow bolus intravenous injection
followed by drip infusion during neutron irradiation, while
FBPA is administered by a single bolus injection. Because
of these differences, the predictive value of FBPA PET for
BPA-fr accumulation in the tumor and normal tissues re-
mains unclear.
In the preset experiment, we first measured the radio-
activity accumulation in transplanted tumors and normal
organs in rats by means of PET/CT carried out after ad-
ministration of a tracer dose of FBPA. We then adminis-
tered a therapeutic dose of BPA-fr and quantified the
absolute concentration of 10B in autopsy specimens by
means of inductively coupled plasma optical emission
spectrometry (ICP-OES). The correlations between the
10B concentrations after BPA-fr injection and the uptake
values of FBPA in FBPA PET were examined in the tu-
mors and normal organs.Methods
Synthesis of L-[18F] FBPA
FBPA was prepared as described previously [4], although
with several modifications, using an F-1 synthesizer
(Sumitomo Heavy Industries, Tokyo, Japan). In brief, 18
F-acetylhypofluorite was bubbled at a flow rate of
600 mL/min at room temperature into 5 mL of trifluor-
oacetic acid containing 30 mg of 4-borono-L-phenylala-
nine. Next, trifluoroacetic acid was removed by passing
N2 under reduced pressure at a flow rate of 200 mL/min.
The residue was dissolved in 3 mL of 0.1% acetic acid,
and the solution was applied to YMC-Pack ODS-A, a
high-performance liquid chromatography column (20 mm
in inner diameter × 150 mm in length; YMC, Kyoto,
Japan), under the following conditions: mobile phase,
0.1% acetic acid; flow rate, 10 mL/min; ultraviolet detector
at 280 nm; and radioactivity detector. The FBPA fraction
(retention time = 19 to 21 min) was collected. After drying
of the FBPA fraction, the residue was dissolved in saline.
The radiochemical purity of FBPA was >98%, and the
specific activity at the end of the synthesis was 49.7 ±
17.3 GBq/mmol as determined by HPLC.Preparation of the BPA-fructose complex
BPA was solubilized at neutral pH for intravenous infu-
sion by allowing it to form a complex with fructose. Injec-
tion solutions of the BPA-fructose complex (BPA-fr) were
prepared at a concentration of 10 mg BPA/0.43 mL using
a previously published procedure with modifications [6].
Glioma tumor model preparation
Seven male F344/NJcl-rnu/rnu rats (11 to 13 weeks;
241.7 ± 28.0 g) obtained from CLEA Japan (Tokyo, Japan)
were used for this study. The RGC-6 rat glioma cell was
obtained from RIKEN BRC (Tsukuba, Japan) through the
National Bio-Resource Project of MEXT, Japan. RGC-6
cells (1.9 × 107) were implanted subcutaneously as a
cell/Matrigel mixture into the backs of F344 rats. On
day 20 after the tumor implantation, the rats were starved
for 8 h. The animal studies were conducted with the ap-
proval of the Animal Care and Use Committee of Osaka
University.
FBPA PET/CT procedure
Rats anesthetized by inhaled 2% isoflurane plus 100%
oxygen at 2 L/min were intravenously injected with
FBPA at a dose of 30.5 ± 0.7 MBq (1.69 ± 1.21 mg/kg
body weight) [11]. To minimize the influence of BPA-fr
accumulation from FBPA, the dose of FBPA was set as tra-
cer dose. Then, the rats were imaged with micro PET/CT
(Inveon; Siemens Medical Solutions, Knoxville, TN, USA)
in a prone position. In four of seven rats, dynamic images
were obtained during 1 h (30 frames of 2 min) after the
injection. To measure FBPA in comparison with BPA-fr
quantification, static images were obtained in seven rats
1 h after the injection for 10 min (5 min/per bed position,
two bed positions). All PET images were reconstructed by
2D ordered-subset expectation maximization (16 subsets,
4 iterations) with a 128 × 128 pixel image matrix. The
spatial resolution at the center of the field of view (FOV)
was 1.62 mm [12]. The CT images were acquired at a tube
voltage of 80 kVp and tube current of 140 μA for scatter
and attenuation correction. The injected radioactivity of
FBPA was measured by a well-type scintillation counter
(BeWell; Molecular Imaging Labo, Osaka, Japan). Regions
of interest (ROIs) were placed over the tumor, brain, lung,
liver, spleen, pancreas, small intestine, large intestine, kid-
ney, and blood pool in the left ventricle on the decay-
corrected PET images with reference to CT images. The
maximum and average counts in the voxel were automat-
ically converted to radioactivity per milliliter (Bq/mL) by
the cross-calibration factor in the PET reconstruction
process. Time-activity curves were plotted for both the
tumor and the normal tissues, excluding the spleen and
intestine. Based on the assumption that tissue density is
1 g/mL, values were converted to radioactivity per gram
of tissue (Bq/g). The percentage of the injected dose per
Table 1 Absolute of boron concentration after injection
of 40 mg (167.32 ± 18.65 mg/kg body weight) BPA by
ICP-OES (ppm)
Absolute of boron concentration (ppm)
Median Mean ± SD
Tumor 24.31 27.56 ± 8.42
Brain 7.73 7.66 ± 1.15
Lung 17.76 15.12 ± 3.83
Liver 13.80 14.93 ± 2.49
Spleen 19.04 20.48 ± 4.59
Pancreas 50.66 52.25 ± 12.06
Small intestine 16.45 16.46 ± 2.49
Large intestine 12.97 13.21 ± 1.53
Kidney 77.64 83.06 ± 16.08
Blood 12.44 12.25 ± 0.96
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radioactivity per gram (Bq/g) by the injected amount of
radioactivity (Bq).
10B assay in RGC-6 glioma-bearing F344 rats after BPA-fr
injection
One hour after the PET/CT scan, 40 mg BPA-fr (167.32 ±
18.65 BPA mg/kg body weight) was injected bolus through
the tail vein of each rat. The rats were sacrificed 1 h after
the BPA-fr injection, and the following tissue samples
were collected: tumor, brain, lung, liver, spleen, pancreas,
small intestine, large intestine, kidney, and blood. The ab-
solute 10B concentrations in the tissue samples were mea-
sured by ICP-OES (Vista-MPX ICP-OES spectrometer,
Seiko Instruments, Chiba, Japan) [13,14]. The concentra-
tions of 10B from BPA-fr in the normal tissues and tumor
tissues were normalized to %ID/g. A part of the tumor
tissue was stained with hematoxylin and eosin for light
microscopy examination.
Data analysis
The concentrations of FBPA and BPA-fr in the tissues,
which were measured by PET/CT and ICP-OES, respect-
ively, were shown as mean ± SD. The Pearson product-
moment correction coefficients were calculated to evaluate
the correlations between the FBPA accumulations mea-
sured by PET/CT and BPA-fr accumulations measured by
ICP-OES. Wilcoxon's signed-rank test was performed to
compare the accumulation level of FBPA estimated by
PET/CT and accumulation level of BPA-fr measured by
ICP-OES in each of the tissues. All the statistical analyses
were performed with the SPSS software (Version 17, SPSS
Inc., Chicago, IL, USA), and a p value of less than 0.05 in-
dicated a significant difference.
Results
Table 1 shows absolute values of boron concentrations
measured by ICP-OES in the tissues. The highest con-
centration was found in the kidney, followed by that in
the pancreas and the glioma tumor tissue.
Figure 1 shows the time-activity curves based on aver-
age count of the tumor and several organs in F344 rats
after administration of FBPA. Time-activity curves of
the tumor and normal tissues showed various patterns
of rapidly increasing FBPA uptake up to 20 min, which
stabilized or decreased thereafter gradually. Dynamic
PET data demonstrated the ratio of tumor to blood (1.24,
1.67, and 1.71) at 10, 30, and 60 min after administration
of FBPA, respectively.
The accumulation levels of FBPA measured by PET/CT
and expressed as %ID/g demonstrated significant positive
correlations with the accumulation levels of BPA-fr mea-
sured by ICP-OES and expressed as %ID/g; the regression
lines were as follows: y = 1.21x − 0.31 (r = 0.92, p < 0.05)for FBPA accumulation based on the maximum count and
y = 0.97x − 0.34 (r = 0.91, p < 0.05) for FBPA accumulation
based on the average count (Figures 2 and 3).
Figure 4 depicts the FBPA PET/CT images of a RGC-6
glioma-bearing F344 rat. Significant accumulation in the
tumor and high radioactivity contrast between the tumor
and normal tissues are observed. High uptakes of FBPA
in the kidneys and pancreas of the rats are seen.
Table 2 shows the accumulation levels of FBPA mea-
sured by PET/CT and accumulation levels of BPA-fr
measured by ICP-OES, expressed as %ID/g of tissue.
The estimated values by FBPA PET based on the max-
imum count in the blood, brain, liver, pancreas, and
tumor were similar to the values measured by ICP-OES.
The differences did not exceed 15% in any of these tis-
sues. In the lung, small intestine, and large intestine, the
FBPA accumulation measured by FBPA PET based on
the maximum count and average count was significantly
underestimated. In the tumor, the value based on the
average count was significantly underestimated. In the
kidney, the value based on the maximum count was sig-
nificantly overestimated.
Figure 5 shows a light microscopy image of a
hematoxylin-eosin-stained section (scale bars = 100 μm)
of the glioma, showing the heterogeneity of the lesion.
Discussion
In this study, we demonstrated a significant correlation
between the concentrations of 10B and accumulation
levels of FBPA in tumors and various normal organs,
despite the differences in the chemical structure and
dose administered between BPA-fr and FBPA.
Kabalka et al. reported the optimal time for neutron
exposure after infusion of BPA-fr. They reported that
the tumor-to-blood activity ratio of humans appeared to
plateau after 60 mm [10]. In the present study, the time
Figure 1 Time-activity curve. Based on average count of tumor and normal organs in F344 rats after administration of FBPA.
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considered appropriate because the tumor-to-blood ratio
becomes stable. More time points are needed for in-depth
dosimetric studies. Nevertheless, one time point of 1 h is a
good compromise to obtain a quantitative value that can
be correlated with other variables.
Yoshimoto et al. recently reported that FBPA is predom-
inantly transported via the L-type amino acid transporter
in human glioblastoma cells [15]. They also demonstrated
that uptake of FBPA into human glioblastoma cells was
inhibited by high concentrations of BPA in the medium,
suggesting that FBPA and BPA share the same transporter
system. Imahori et al. also reported that the 10B concen-
trations in surgically removed specimens of glioblastoma
after administration of BPA-fr at therapeutic doses were
predicted by using the rate constants of FBPA PET [16].Figure 2 Correlation between accumulation levels based on
maximum count. Correlation between the accumulation level of
BPA-fr measured by ICP-OES and that of FBPA estimated by FBPA
PET/CT based on the maximum count in a rat model.In this study, the injected dose of BPA-fr was about 100
times higher than that of FBPA. Notwithstanding, signifi-
cant correlations were observed between the amounts of
BPA-fr and FBPA accumulated in the tumors as well as
normal organs. Our results suggest that FBPA PET can be
used to estimate the amount of BPA accumulation in the
normal surrounding tissues during BNCT. The accumula-
tion levels of both BPA and FBPA in the pancreas were
remarkably high (2.73 and 2.42 %ID/g, respectively). This
finding suggests that radiation injury of the pancreas
should be anticipated when BNCT is employed for ab-
dominal cancers.
There are several reports suggesting similar pharma-
cokinetics between BPA-fr and FBPA in normal tissues/
organs. Wang et al. [17] measured the radioactivity in
glioma and normal tissues after injection of FBPA-fr by a
γ-scintillation counter and compared the 10B concentra-
tions by ICP-MS after injection of BPA-fr as the tumor-
to-normal tissue ratio. The tumor-to-normal tissue uptake
ratio of FBPA-fr was parallel to that of BPA-fr. Yang et al.
[18,19] reported the pharmacokinetic analysis of FBPA
and BPA-fr after ultrasound-induced blood-brain barrier
disruption. Ishiwata et al. [20] reported that the ratios of
the concentrations of FBPA to those of BPA in the tumor,
blood, and muscle measured by a NaI(Tl) gamma counter
and ICP-AES, respectively, ranged from 0.70 to 1.00.
These reports lend support to our view that FBPA PET
can be used for the assessment of BPA accumulation in
normal tissues/organs during BNCT in an attempt to
avoid radiation injury.
In BNCT, the subcellular location of 10B is of critical im-
portance for the cell-killing effect, because the trace
ranges of α particles and 7Li are very short. Chandra et al.
[21] reported that there was no significant difference in
the intracellular distribution between FBPA and BPA as
Figure 3 Correlation between accumulation levels based on average count. Correlation between the accumulation level of BPA-fr measured
by ICP-OES and that of FBPA estimated by FBPA PET/CT based on the average count in a rat model.
Figure 4 PET/CT images of a RGC-6 glioma-bearing F344 rat. PET/CT fused images of F344 male rats with RGC-6 glioma xenografts 60 min
after injection of approximately 30 MBq of FBPA. (a) At the level of brain, (b) at the level of heart and transplanted tumor, (c) at the level of pancreas
and liver, (d) at the level of kidneys, and (e) at the level of bladder (all transaxial images). FBPA accumulation in the tumor was found in the plane
(b) indicated by an arrow. In the planes (c), (d), and (e), high accumulations were found in the pancreas, kidneys, and bladder, respectively.
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Table 2 Biodistribution of BPA-fr and [18F] FBPA in various organs of RGC6 glioma-bearing Fischer 344 rats (n = 7)
Accumulation of BPA-fr by
ICP-OES (%ID/g)
Accumulation of FBPA by PET
based on maximum count (%ID/g)
Accumulation of FBPA by PET
based on average count (%ID/g)
Median Mean ± SD Median Mean ± SD Median Mean ± SD
Tumor 1.27 1.44 ± 0.44 1.34 1.36 ± 0.31 0.80 0.79 ± 0.18*
Brain 0.40 0.40 ± 0.06 0.41 0.43 ± 0.07 0.26 0.27 ± 0.07*
Lung 0.93 0.79 ± 0.20 0.39 0.38 ± 0.05* 0.23 0.25 ± 0.05*
Liver 0.72 0.78 ± 0.13 0.78 0.78 ± 0.14 0.59 0.61 ± 0.12
Spleen 0.99 1.07 ± 0.24 0.89 0.88 ± 0.10 0.59 0.58 ± 0.08*
Pancreas 2.65 2.73 ± 0.63 2.64 2.42 ± 0.63 1.76 1.63 ± 0.36*
Small intestine 0.86 0.86 ± 0.13 0.48 0.52 ± 0.10* 0.36 0.36 ± 0.08*
Large intestine 0.68 0.69 ± 0.08 0.44 0.46 ± 0.09* 0.30 0.30 ± 0.07
Kidney 4.06 4.34 ± 0.84 5.52 5.70 ± 0.89* 4.56 4.66 ± 0.76
Blood 0.65 0.64 ± 0.05 0.59 0.61 ± 0.14 0.45 0.47 ± 0.10*
*p < 0.05 compared to BPA-fr by ICP-OES.
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FBPA PET would reflect the intracellular distribution of
BPA-fr and predict the therapeutic effect of α particles
and 7Li which have short track ranges.
In our study, underestimations by FBPA PET were
observed in the lung and intestines. One of the reasons
for this may be the partial volume effect, because of the
limit of resolution of PET. The partial volume effect,
which occurs at sizes less than or equal to three times
the full width at half maximum, was not corrected
for this study [22,23]. The full width at half maxi-
mum of the PET system used in this study in axial
resolutions at the center of the FOV was 1.62 mm;
therefore, differences in the sizes of the tissues may
influence the %ID/g. Especially in the lung and intestines,
the influence of the partial volume effect is serious,Figure 5 Representative light microscopy images of the glioma (hem
(b), indicating the heterogeneity of the tumor components.because the regions of interest on the PET images contain
air [24].
On the other hand, overestimation was noted in the
kidney. FBPA is metabolically stable. During the initial
1 h, about half of the injected amount of tracer was
passed into the urine [25]. In the kidney, contamin-
ation with the count from the urine contained in the
ureter or renal pelvis should be considered on FBPA
PET images.
In the tumor, there was a 40% difference between the
maximum count and average count on FBPA PET im-
ages. The slight overestimation of the accumulation level
in the tumor in this study is mainly because gliomas
consist of heterogeneous tissue components, including
viable portions, central necrosis areas, and peritumoral
infiltration areas [26] (Figure 5).atoxylin-eosin staining). Area (a) has a lower cell density than area
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treatment of malignant melanoma [27], malignant brain
tumors [5,16,28-30], and cancer of the neck [31]. In re-
cent years, adoption of BNCT has expanded to liver can-
cer [32], breast cancer, and lung cancer [33]. Therefore,
prediction of the absolute concentration of BPA in the
normal tissues in individual patients is very important
to minimize the radiotoxicity to normal healthy tissues
during BNCT.
Our study had some limitations. First, the method of
administration of BPA-fr for BNCT is different from the
infusion method adopted for administration of FBPA for
PET/CT, especially because PET examination requires
only a low dose of FBPA. BPA is administered via intra-
venous infusion. Therefore, determination of the offset
according to the infusion method of BPA-fr is required
to ensure the accuracy of the clinical data.
Second, the biodistribution of FBPA in animals differs
from that in humans [25]. Especially in the pancreas, the
expression levels of LAT1 between rats and humans are
different. The accumulation levels of FBPA and BPA-fr
determined in this research may therefore not be applic-
able to clinical cases. Further clinical FBPA PET study is
required to determine BPA-fr distribution in the cancer
patients.
Conclusions
In this study, we demonstrated the existence of clear
correlations between the accumulation levels of BPA-fr
and FBPA in the transplanted glioma cells and nor-
mal organs in rat xenograft models. This preclinical
study indicates the validity of FBPA PET for predicting
BPA-fr accumulation in tumors and normal tissues/or-
gans in BNCT. Further studies are required to estimate
the 10B concentrations in tissues following BPA-fr ad-
ministration according to a clinical protocol, such as
slow infusion and drip infusion of BPA during neutron
irradiation.
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